ITS Interim

 
Fund Quotes for ITS Interim top ^
  • Category: Short Government
  • Morningstar Rating: 3 Stars
Sign-up for sfitx investment picks

 
News Articles for ITS Interim top ^
2014/4/30
THE HAGUE, The Netherlands , April 30, 2014 /PRNewswire/ -- The Board of Royal Dutch Shell plc (NYSE: RDS.A) (NYSE: RDS.B) today announced a revised intended timetable for the 2014 quarterly interim dividends.
Sign-up for Royal Dutch Shell Plc - Revised 2014 Interim Dividend Timetable investment picks
2014/5/18
Severe effects expected on employment and the Negev's economy.
Sign-up for ICL's Comment to Sheshinski Interim Recommendation: The Commission's Interim Recommendations Might Force ICL to Stop Investing in Israel and Focus on Cost Cutting investment picks
TORONTO, April 16, 2014 (GLOBE NEWSWIRE) -- SMTC Corporation (Nasdaq:SMTX) ("SMTC"), a global electronics manufacturing services provider, today announced the appointment of Jim Currie as its Interim Chief Financial Officer effective April 16, 2014.
Sign-up for SMTC Appoints Jim Currie as Interim Chief Financial Officer investment picks
DUBLIN, May 1, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA) , a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced today that it will host a live webcast and conference call on Friday, May 2, 2014 at 4:30 p.m. ET (or 1:30 p.m. PT) to review interim clinical data from the ongoing Phase 1 study of NEOD001 presented as part of the poster session at the XIV International Symposium on Amyloidosis earlier this week.
Sign-up for Prothena to Host Webcast and Conference Call to Discuss Interim Phase 1 Data of Ongoing NEOD001 Study in Patients With AL Amyloidosis on May 2 investment picks
THE WOODLANDS, Texas , May 1, 2014 /PRNewswire/ -- CB&I (NYSE:CBI) today declared an interim dividend on common stock of $0.07 per share, payable June 30, 2014 , to shareholders of record as of June 20, 2014 .
Sign-up for CB&I Declares Interim Common Stock Dividend investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1114462&ProfileId=051205&sourceType=1 LONDON, UNITED KINGDOM --
Sign-up for Anglo Pacific Group PLC: Interim Management Statement investment picks
NEW YORK, April 29, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) , a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced that it has completed the enrollment of its OHR-002 Phase II clinical trial evaluating Squalamine Eye Drops for the treatment of the wet form of age related macular degeneration ("wet-AMD"). The study has enrolled a total of 142 patients, and the Company expects to announce interim data on the first 60 patients completing the protocol in June this year.
Sign-up for Ohr Pharmaceutical Announces Completion of Enrollment in Phase II Clinical Trial of Squalamine Eye Drops in Wet-AMD investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0942632001&sourceType=1 http://www.ccnmatthews.com/logos2/rsi-un.gif MONTREAL, QUEBEC --
Sign-up for Rogers Sugar Inc.: Interim Report for the 2nd Quarter 2014 Results investment picks
COPENHAGEN, Denmark, May 8, 2014 (GLOBE NEWSWIRE) -- Performance for the period (unaudited) (Comparative figures for 2013 are shown in brackets / revenue growth is measured in local currencies) Revenue and operating profit (EBITDA) in Q1 was strong.
Sign-up for Three-Month Interim Report (Q1) 2014 investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0945476001&sourceType=1 http://www.ccnmatthews.com/logos/20090514-E-L.jpg TORONTO, ONTARIO --
Sign-up for E-L Financial Corporation Limited Announces March 31, 2014 Interim Financial Results investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0945163001&sourceType=1 http://www.ccnmatthews.com/logos/20090614-orslo.JPG LONDON, UNITED KINGDOM --
Sign-up for Orsu Metals Corporation Interim Results for the Three Months Ended March 31, 2014 (Unaudited) investment picks
LEXINGTON, Ky.
Sign-up for Lexmark appoints Gary Stromquist as interim chief financial officer investment picks
2014/5/15
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0946380001&sourceType=1 TORONTO, ONTARIO --
Sign-up for The Intertain Group Limited Interim Financial Statements investment picks
2014/5/23
KANSAS CITY, Mo.
Sign-up for APT Group, Inc. Announces Officer Transition; Selects Current Executive for Interim Role investment picks
VANCOUVER, British Columbia, May 21, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that recent advances in its clinical programs were presented at the 17 th Annual Meeting of the American Society of Gene and Cell Therapy, which is taking place in in Washington, DC, May 21 to 24.
Sign-up for Tekmira Presents Positive Interim Results on Phase I/II Clinical Programs investment picks
NEW YORK, April 10, 2014 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (Nasdaq:ICPT) common stock between January 9, 2014 and January 10, 2014.
Sign-up for UPCOMING DEADLINE: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against INTERCEPT PHARMACEUTICALS, INC. and Its Board of Directors and a Lead Plaintiff Deadline of April 22, 2014 -- ICPT investment picks
ANN ARBOR, Mich., April 9, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) , the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that the independent Data and Safety Monitoring Board (DSMB) for the company's ixCELL-DCM Phase 2b clinical trial has recommended continuing the study without modification as planned following an interim review of unblinded safety data from the trial.
Sign-up for Aastrom Reports Data and Safety Monitoring Board Recommendation to Continue ixCELL-DCM Clinical Trial investment picks
TORONTO and SAN FRANCISCO, April 22, 2014 (GLOBE NEWSWIRE) -- Points (TSX:PTS) (Nasdaq:PCOM) , the global leader in loyalty currency management, today announced that it has purchased all of the outstanding shares of Accruity Inc., the San Francisco-based operator of the award-winning PointsHound hotel booking service.
Sign-up for Points International Acquires Travel Booking Service to Showcase Additional Loyalty Commerce Platform Offerings investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
ITS Interim
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Issuer Bid  |  Next: Ivanhoe Energy